<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study reports cytomorphological, histomorphological, and immunological characterization of 608 biopsy cases of canine malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, with epidemiological and clinical data, collected from 7 French veterinary pathology laboratories </plain></SENT>
<SENT sid="1" pm="."><plain>It compares morphological characteristics of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in canines, per the updated Kiel classification system, with those reported in humans, per the World Health Organization (WHO) classification system </plain></SENT>
<SENT sid="2" pm="."><plain>Of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> described, 24.5% and 75.5% were classified as low- and high-grade malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Presenting clinical signs included generalized or localized <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> (82.4%) and extranodal diseases (17.6%) involving the skin (12.34%) and other sites (5.26%) </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemistry confirmed 63.8% B-cell (CD3-, CD79a+), 35.4% T-cell (CD3+, CD79a-), and 0.8% null-cell (CD3-, CD79a-) <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Most B-cell cases (38.49%) were of high-grade <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> polymorphic subtype; most T-cell cases (8.55%), high-grade pleomorphic mixed and large T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes </plain></SENT>
<SENT sid="6" pm="."><plain>Some B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> showed morphologic characteristics consistent with follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> per the Revised European American Classification of Lymphoid <z:hpo ids='HP_0002664'>Neoplasms</z:hpo> and WHO canine classification systems and the WHO human classification system </plain></SENT>
<SENT sid="7" pm="."><plain>Unusual high-grade B-cell subtypes included an atypical high-grade small B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0.66%), Burkitt-type B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (1.64%), plasmacytoid <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0.99%), and mediastinal anaplastic large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0.16%) </plain></SENT>
<SENT sid="8" pm="."><plain>Unusual T-cell subtypes included a previously undescribed high-grade canine <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> T-cell type (1.15%), a rare low-grade prolymphocytic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0.16%), and a recently described high-grade canine T-cell entity--aggressive granulocytic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0.16%) </plain></SENT>
<SENT sid="9" pm="."><plain>Marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were common (10.86%); follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were rare (0.49%) </plain></SENT>
<SENT sid="10" pm="."><plain>Canine primary cutaneous malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes were present (11.84%) </plain></SENT>
<SENT sid="11" pm="."><plain>There was no significant difference between B- and T-cell malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in regard to canine age and sex </plain></SENT>
<SENT sid="12" pm="."><plain>A significant overrepresentation of Boxers (24.19%) was found for T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>